Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6046 AL 6060

α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

Geerts H.

Expert Opin Investig Drugs. 2012 Jan;21(1):59-65. doi: 10.1517/13543784.2012.633510. Epub 2011 Nov 3.

Multi-target-directed ligands in Alzheimer's disease treatment

Bajda M, Guzior N, Ignasik M, Malawska B.

Curr Med Chem. 2011;18(32):4949-75. doi: 10.2174/092986711797535245.

Challenges associated with curcumin therapy in Alzheimer disease

Belkacemi A, Doggui S, Dao L, Ramassamy C.

Expert Rev Mol Med. 2011 Nov 4;13:e34. doi: 10.1017/S1462399411002055.

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type

Dhillon S.

Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000.

Long-term progression of Alzheimer's disease in patients under antidementia drugs

Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B; REAL.FR study group.

Alzheimers Dement. 2011 Nov;7(6):579-92. doi: 10.1016/j.jalz.2011.02.009.

Amelioration of amyloid β-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer's disease

Majlessi N, Choopani S, Kamalinejad M, Azizi Z.

CNS Neurosci Ther. 2012 Apr;18(4):295-301. doi: 10.1111/j.1755-5949.2011.00237.x. Epub 2011 Feb 16.

Systemic and central immunity in Alzheimer's disease: therapeutic implications

Butchart J, Holmes C.

CNS Neurosci Ther. 2012 Jan;18(1):64-76. doi: 10.1111/j.1755-5949.2011.00245.x. Epub 2011 Mar 21.

Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders

Cecon E, Markus RP.

Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):91-9. doi: 10.2174/187221411799015381.

Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial

Ihl R, Tribanek M, Bachinskaya N; GOTADAY Study Group.

Pharmacopsychiatry. 2012 Mar;45(2):41-6. doi: 10.1055/s-0031-1291217. Epub 2011 Nov 15.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. doi: 10.2174/092986711798194351.

Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease

Marcus JN, Schachter J.

J Neurogenet. 2011 Dec;25(4):127-33. doi: 10.3109/01677063.2011.626471.

Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease

Percy ME, Kruck TP, Pogue AI, Lukiw WJ.

J Inorg Biochem. 2011 Nov;105(11):1505-12. doi: 10.1016/j.jinorgbio.2011.08.001. Epub 2011 Aug 19.

Toward a unifying hypothesis in the development of Alzheimer's disease

Balin B, Abrams JT, Schrogie J.

CNS Neurosci Ther. 2011 Dec;17(6):587-9. doi: 10.1111/j.1755-5949.2011.00269.x.

γ-Secretase inhibitors and modulators for Alzheimer's disease

Wolfe MS.

J Neurochem. 2012 Jan;120 Suppl 1(Suppl 1):89-98. doi: 10.1111/j.1471-4159.2011.07501.x. Epub 2011 Nov 28.

Developing β-secretase inhibitors for treatment of Alzheimer's disease

Ghosh AK, Brindisi M, Tang J.

J Neurochem. 2012 Jan;120 Suppl 1(Suppl 1):71-83. doi: 10.1111/j.1471-4159.2011.07476.x. Epub 2011 Nov 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias